8-K: Seer Inc. Reprices Underwater Stock Options and Appoints New Board Member

Seer, Inc. has repriced underwater stock options for employees and appointed Dr. Nicolas Roelofs to its Board of Directors.

Summary

• Seer's Board of Directors approved a repricing of stock options for employees holding options with an exercise price above $2.00 per share.
• The new exercise price for these options is set at $2.00 per share, which was the closing price of the company's stock on October 4, 2024.
• If an employee exercises a repriced option before April 4, 2026, or a change in control, they will pay the original higher exercise price.
• Performance-based vesting conditions for certain 2023 option awards were also amended, with the stock price hurdle now set at 150% of $2.00 per share, previously $6.89.
• The repricing affects approximately 7.9 million shares and aims to retain and motivate employees without additional equity grants or cash compensation.
• Additionally, Dr. Nicolas Roelofs has been appointed to Seer's Board of Directors, bringing extensive experience in the life science tools industry.

Sentiment

Score: 7

Explanation: The document contains positive news regarding board member appointment and a necessary but potentially negative stock option repricing. The repricing is a common practice to retain talent, but it also highlights the company's stock performance issues. Overall, the sentiment is moderately positive.

Positives

• The stock option repricing aims to retain and motivate employees.
• The repricing avoids additional stock dilution and cash compensation.
• The appointment of Dr. Nicolas Roelofs brings significant industry experience to the board.
• The company is taking steps to address underwater stock options, which can improve employee morale.

Negatives

• Employees exercising options before April 4, 2026, will have to pay the original higher exercise price.
• The repricing indicates that a substantial majority of employee stock options were underwater.

Risks

• The company's stock price could fall below the new exercise price, rendering the repriced options underwater again.
• The retention period may not be sufficient to retain all employees.
• The company's future performance is subject to various risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company's future performance is subject to various risks and uncertainties as detailed in their SEC filings, and they do not intend to update forward-looking statements.

Management Comments

• Omid Farokhzad, Chair and CEO of Seer, stated that Nick is a fantastic addition to the board.
• Omid Farokhzad also mentioned that Dr. Roelofs' experience will be valuable as they advance their mission.
• Dr. Roelofs said he is excited to work with the Seer team and leverage his experience to drive their next phase of growth.
• Dr. Roelofs believes Seer is at the leading edge of the expanding proteomics market.

Industry Context

The appointment of Dr. Roelofs, with his extensive experience in life science tools, aligns with Seer's focus on commercializing its proteomics platform. The repricing of stock options is a common practice for companies with underwater options to retain talent.

Comparison to Industry Standards

• Stock option repricing is a common practice in the tech and biotech industries when a company's stock price declines significantly, similar to actions taken by companies like Zynga and GoPro in the past.
• The appointment of experienced board members from companies like Agilent and Bio-Rad is a common strategy for biotech companies to gain expertise and credibility, similar to how companies like Illumina and Thermo Fisher Scientific have structured their boards.
• The use of a retention period with a premium exercise price is a common mechanism to ensure employees remain with the company, similar to strategies used by other companies in the sector.

Management Changes

Stakeholder Impact

• Shareholders may view the repricing as a positive step to retain talent.
• Employees with underwater options will benefit from the repricing.
• The appointment of Dr. Roelofs may increase investor confidence.

Next Steps

• The company will continue to execute its business plan.
• The company will work to integrate Dr. Roelofs into the board.
• Employees will need to decide whether to exercise their repriced options.

Key Dates

Keywords

stock options, repricing, board of directors, proteomics, life sciences, equity incentive plan, executive compensation, employee retention, corporate governance